Innovative drugs against Chagas disease
Chagas disease, also known as American trypanosomiasis, is caused by infection with the protozoan parasite Trypanosoma cruzi. The Pan American Health Organization (PAHO) estimates that 7.7 million persons currently have T. cruzi infection, from the southern and southwestern United States to central Argentina and Chile. To date, the present treatments not solve the serious consequences of this disease.
This project is being performed in collaboration with the pharmaceutical company Laboratorio Silanes IDF, S.L., and the Facultad de Ciencias (Uruguay), which researh lines are:
Search of new lead compounds by means of artificial neuronal networks, optimization of the pharmacological properties and synthesis of new antichagasic drugs.
Design, optimization and synthesis of new cruzipain inhibitors by means of docking studies.